

Bioresorbable scaffolds on the bench

John Ormiston^{1,2,6*}, MBChB; Pascal Motreff³, MD; Olivier Darremont⁴, MD; Bruce Webber², MHSc; Patrice Guerin⁵, MD; Mark Webster^{2,6}, MBChB

1. Mercy Angiography, Auckland, New Zealand; 2. University of Auckland School of Medicine, Auckland, New Zealand; 3. University Hospital, Clermont-Ferrand, France; 4. Clinique Saint-Augustin, Bordeaux, France; 5. L'Université de Nantes, Nantes, France; 6. Auckland City Hospital, Auckland, New Zealand

The complete references and the accompanying supplementary data are published online at: http://www.pcronline.com/eurointervention/V_issue/40

KEYWORDS

- bifurcations
- bioresorbable
- scaffolds
- strut fracture

Abstract

Bioresorbable scaffolds (BRS) in bifurcations have all of the potential advantages of BRS in non-bifurcating lesions and, in addition, the absorption of side branch (SB) ostial struts may at least partially release the branch from “jail”. Polymeric BRS struts may break when post-dilated beyond their safe limits and multiple fractures may lead to adverse clinical events. Bench testing provides insights into the behaviour of different BRS in bifurcations and helps the interventional cardiologist to choose, deliver and post-dilate appropriately. Bench testing of polymeric BRS must be in a water bath at 37°C as polymer performance is temperature sensitive. Balloon dilatation through the side of a BRS or a durable metallic stent causes distortion corrected by mini-kissing balloon post-dilatation (mini-KBPD) where the SB balloon extends only a short distance into the main branch (MB), limiting the length of MB scaffold exposed to the inflation of two balloons. The safe pressure threshold for SB dilatation of a 3.0 mm Absorb scaffold with a 3.0 mm non-compliant balloon is 10 atm and for mini-KBPD with two 3.0 mm balloons it is 5 atm. Strategies such as culotte, crush and simultaneous kissing scaffolds (SKS) may not be appropriate for the current Absorb scaffold.

*Corresponding author: Mercy Angiography, PO Box 9911, Newmarket, Auckland 1023, New Zealand.
E-mail: johno@mercyangiography.co.nz

Introduction

The potential advantages of bioresorbable scaffolds (BRS) compared to durable stents in non-bifurcating lesions¹⁻³ are likely to apply to bifurcations with the additional advantage that resorption of those struts across the side branch is expected to, at least partially, release the branch from “jail”^{4,5}.

The struts of some polymeric scaffolds break more readily than metallic struts, potentially leading to adverse events⁶. Different polymeric BRS perform in different ways from each other and from both resorbable and durable metallic DES. Bench testing can provide insights to help guide safe delivery, deployment and post-dilatation. Strategies appropriate for one BRS design may not be appropriate for another. While the magnesium alloy BRS behaves acutely more like a conventional metal DES, a manufacturing challenge is to slow the resorption to oppose negative remodelling².

Results of the bifurcation bench testing of a small number of Absorb scaffolds (Abbott Vascular, Santa Clara, CA, USA) have been published^{7,8}. We present here some of the results of our BRS bench testing and review some of the limited published data.

Testing and imaging conditions

It is essential that bench testing of polymeric BRS is carried out in liquid at 37°C⁹. We use a water bath with close water temperature control as even a few degrees change can alter polymeric performance. We use a number of different mock coronary arteries whose design can follow Murray’s Law^{10,11}. We image deployments with fluoroscopy and photography, and also image deployed scaffolds with microcomputed tomography¹⁰. We use environmental scanning electron microscopy to examine scaffolds and coatings.

Bioresorbable scaffold designs

Of six BRS designs for which we have data (**Figure 1**), five are constructed from polymers and one, the DREAMS (Biotronik, Berlin, Germany), from magnesium alloy. Data are for 3.0 mm examples of scaffolds. The potential cell diameter is important for side branch (SB) access as a small cell may not allow device passage and have a greater risk of strut fracture with balloon inflation. For the Absorb (Abbott Vascular) and DESolve scaffolds (Elixir Medical, Sunnyvale, CA, USA), the cell diameter of approximately 3.0 mm is adequate and it is likely that the FORTITUDE™ (Amaranth Medical, Mountain View, CA, USA) device is similar (**Figure 1**)⁹. The DREAMS potential cell size is likely to be larger because there are two not three connectors between hoops. The ReZolve (REVA Medical Inc., San Diego, CA, USA) and ART (Arterial Remodeling Technologies, Noisy le Roi, France) have some cells that are small and suboptimal for bifurcation strategies (**Figure 1**). While REVA Medical has a new design (Fantom™) that appears to be similar to Absorb, we have not had the opportunity to bench test and do not have specific data yet.

While multiple scaffold fractures and protrusion of many struts into the lumen are likely to have adverse consequences⁶, single strut fracture may have little clinical impact⁹. When a bioresorbable scaffold is post-dilated with progressively increasing balloon sizes and




Figure 1. Six different bioresorbable scaffolds. The manufacturers, construction material, design, connector number, antiproliferative drug and strut thickness in microns (including coating thickness) are shown. The red broken lines outline a cell between struts.

balloon pressures, the chance of strut fracture increases depending on the construction material and design of the scaffold. This fracture risk is important when using BRS in bifurcations because of the need for safe post-dilatation strategies⁹. Our testing showed that for a 3.0 mm Absorb scaffold fracture occurs with MB post-dilatation with balloon diameters larger than 3.8 mm (**Online Figure 1**)⁹. Strut fractures occur with similar balloon sizes for the ART and ReZolve designs while the DESolve did not fracture at sizes below 4.7 mm¹² and DREAMS did not fracture at 5.3 mm.

Side branch dilatation and distortion

Dilatation through the side of stents and scaffolds causes distortion^{9,13} with malapposition of the scaffold opposite the side branch, narrowing distal to the SB and desirable effects of some clearance of struts from the SB ostium and some protrusion of struts into the SB (**Figure 2**). There are safe thresholds for mini-KBPD of Absorb scaffolds⁹ and, when these are exceeded (**Figure 2B**), strut fracture occurs.

For a 3.0 mm Absorb scaffold, and SB dilatation with a 3.0 mm NC balloon there is a safe threshold⁹ of 10 atm at or below which strut fracture does not occur (**Figure 3A**). With mini-KBPD, the safe threshold for a 3.0 mm Absorb scaffold with two 3.0 mm NC balloons is 5 atm⁹ at or below which fracture does not occur (**Figure 3B**).

Post-dilatation strategies

Post-dilatation strategies are described in **Figure 4**.

General policy for deploying an Absorb scaffold in a bifurcation

When deploying an Absorb in the bifurcation MB in a provisional side branch strategy⁹, a guidewire (0.014”) is passed to each branch. In contrast to the European Bifurcation Club recommendations for




Figure 2. Side branch dilatation for a 3.0 mm Absorb and mini-kissing balloon post-dilatation. The 3.0 mm Absorb scaffold was deployed in a phantom in a water bath at 37°C. A) The side branch is dilated with a 3.0 mm non-compliant balloon (green) at 10 atm. While side branch dilatation cleared struts from the side branch ostium and protruded some struts into the side branch (A), it also caused distortion with malapposition of struts opposite to the side branch (white double-headed arrow) and narrowing of the scaffold distal to the side branch (yellow double-headed arrow) but no strut fractures at this pressure. B) The mini-kissing balloon post-dilatation with two 3.0 mm non-compliant balloons at 10 atm exceeded the safe threshold⁹, extensively fracturing struts.




Figure 3. Side branch dilatation and mini-kissing post-dilatation. A) Individual 3.0 mm scaffolds after 3.0 mm side branch balloon dilatation and increasing pressure. B) Similar scaffolds with mini-KBPD with two 3.0 mm balloons and increasing pressure. The green points represent inspection with no fracture and the red stars represent fractured strut(s). (Modified from EuroIntervention⁹ with permission from Europa Digital & Publishing)




Figure 4. Post-dilatation strategies. With conventional kissing balloon post-dilatation (A), the main branch balloon and the proximal portion of the side branch balloon lie in the main branch with proximal markers aligned (white arrowheads). With mini-kissing balloon post-dilatation (B), a short length of side branch balloon lies in the main branch but does not extend back to the proximal portion of the scaffold. With “snuggle” balloons (C), the side branch balloon lies entirely within the side branch. The double-headed yellow arrows indicate that conventional kissing post-dilatation exposes the proximal scaffold to two balloons (A) whereas with mini-kissing balloon post-dilatation (B) and “snuggle” balloons (C) the proximal scaffold is exposed to only one balloon. Balloon diameters in the bifurcation (red double-headed arrows) are similar for the kissing strategies (A & B) but less for “snuggle” (C).

metallic stents^{14,15}, we recommend sizing the scaffold to the proximal main branch to allow safer proximal post-dilatation. Following proximal optimisation¹⁴, if there is need for side branch dilatation, we rewire the side branch through the side of the scaffold then dilate through the side of the scaffold. Distortion is corrected with mini-KBPD. Balloon pressures used are below the safe thresholds⁹ (**Figure 3**). If necessary, we would stent or scaffold the side branch using a “T” strategy.

Culotte scaffold deployment

The two-scaffold culotte bifurcation strategy with a 3.5 mm MB scaffold and a 3.0 mm SB scaffold is shown in **Figure 5** and in **Moving image 1**. A 3.5 mm balloon passed from the proximal MB through the side of the SB scaffold was inflated to 12 atm. After this, for mini-KBPD this 3.5 mm MB balloon and a 3.0 mm balloon in the SB were inflated simultaneously to 7 atm. One of these post-dilatation manoeuvres caused a single connector fracture in the SB scaffold. This type of fracture is probably of no clinical significance as connectors do not provide radial support and function only to hold hoops together. In addition, this fractured connector did not protrude into the lumen. We have performed culotte scaffold deployment in only a small number of scaffolds.




Figure 5. Culotte bifurcation scaffolding with a 3.5 mm Absorb in the main branch (white scaffold) and a 3.0 mm scaffold from the main to side branch (red scaffold). Yellow arrows in panels A, B and C indicate a connector fracture in the side branch scaffold. The asterisk indicates two layers of struts. Some side branch struts protrude into the main branch in A. There is no side branch obstruction (D).

Mini-crush scaffold bifurcation deployment

The two-scaffold mini-crush bifurcation strategy^{16,17} is demonstrated in **Online Figure 2** and **Moving image 2**.

Simultaneous kissing scaffold deployment

The two Absorb scaffold strategy, called simultaneous kissing scaffolds (SKS)¹⁸, is shown in **Online Figure 3** and **Moving image 3**. We have performed only a small number of these deployments.

Scaffold coating integrity after withdrawal of a wire trapped between scaffold and phantom wall

Withdrawal of a wire trapped between an Absorb and the phantom wall causes a line of damage to the polymeric coating (**Online Figure 4**). However, the area of scaffold bare of coating is relatively small and much smaller than the gaps between struts, so is unlikely to have clinical importance.

Summary

The interventionalist needs to understand the different BRS performance characteristics in order to select appropriate coronary lesions for BRS, and to deliver, deploy and post-dilate BRS appropriately and safely. Because polymeric BRS struts may break more readily

than those of metallic stents it is essential that the interventionalist understands safe balloon size and pressure post-dilatation limits. It is likely that the “T” strategy with a metallic drug-eluting stent is the best strategy if, after deployment of an MB scaffold, the SB needs treatment. The culotte, crush and SKS strategies have important disadvantages, including technical difficulty, multiple strut layers and the potential for strut fracture. The withdrawal of a trapped wire during a provisional SB strategy causes a limited amount of polymer coating damage.

Funding

The Auckland Heart Group Charitable Trust.

Conflict of interest statement

J. Ormiston is an advisory board member for Abbott Vascular and Boston Scientific and has received minor honoraria from them. O. Darremont is an advisory board member for Abbott Vascular. The other authors have no conflicts of interest to declare.

References

The references can be found in the online version of the paper.

Online data supplement

Online Figure 1. Absorb scaffold post-dilatation and fracture.

Online Figure 2. Mini-crush Absorb scaffold deployment.

Online Figure 3. Simultaneous kissing scaffolds (SKS).

Online Figure 4. Environmental scanning electron microscope images of an Absorb scaffold.

Moving image 1. Culotte bifurcation scaffolding with a 3.5 mm Absorb in the main branch (white scaffold) and a 3.0 mm scaffold from the main to side branch (red scaffold).


Moving image 2. Mini-crush Absorb scaffold deployment. The deployment of the main branch 3.5 mm scaffold (white) has crushed a short length of 3.0 mm side branch scaffold (red). There are three layers of crushed strut each 157 μ m thick. Main branch scaffold post-dilatation with a 3.5 mm NC balloon was followed sequentially by a side branch post-dilatation with a 3.0 mm NC balloon each at 16 atm then kissing post-dilatation (same balloons) at 5 atm. The side branch struts (red) have not been fully cleared from the side branch ostium.

Moving image 3. Simultaneous kissing scaffolds (SKS). While the scaffolds can be deployed simultaneously through a large guide, the same result can be achieved by sequential deployment then kissing post-dilatation. The lumens are asymmetrical and two layers of struts partition the main branch.


Online data supplement

References


1. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. *Lancet*. 2008;371:899-907.
2. Ormiston JA, Serruys PW. Bioresorbable coronary stents. *Circ Cardiovasc Interv*. 2009;2:255-60.
3. Ormiston JA, Webster MW, Onuma Y, Serruys PW. Bioresorbable coronary scaffolds, in *Coronary Stenting: a companion to Topol's textbook in interventional cardiology*. Philadelphia, PA, USA: Elsevier; 2014.
4. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. *Lancet*. 2009;373:897-910.
5. Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen N, Freire R, Kijkstra J, Tu S, van Mieghem N, van Soest G, de Jaegere P, Serruys P, Zijlstra F, van Geuns RJ, Regar E. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. *J Am Coll Cardiol*. 2014;64:2343-56.
6. Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric vascular scaffolds: a cautionary tale. *Circ Cardiovasc Interv*. 2011;4:535-8.
7. Sgueglia G, D'Errico F, Gioffre G, De Santis A, Gaspardone A. First ad hoc bioresorbable vascular scaffold bench test: a glimpse into percutaneous bifurcation intervention. *Int J Cardiol*. 2014;172:604-6.
8. Dzavik V, Colombo A. The absorb resorbable scaffold in coronary bifurcations. Insights from bench testing. *JACC Cardiovasc Interv*. 2014;7:81-8.
9. Ormiston JA, Webber B, Ubod B, Webster MW, White J. Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-dilatation strategies. *EuroIntervention*. 2015;10:1169-77.
10. Ormiston JA, Webster MW, Webber B. Percutaneous intervention for coronary lesions: Bench testing in the real world, in Waksman R and Ormiston J, eds. *Bifurcation Stenting*. West Sussex, UK; Wiley-Blackwell; 2012. p.83-88.
11. Murray CD. The Physiology Principle of Minimum Work. I. The Vascular System and Cost of Blood Volume. *Proc Natl Acad Sci USA*. 1926;12:207-14.
12. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, Bhat V, Yan J, Abizaid A. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. *JACC Cardiovasc Interv*. 2014;7:89-99.
13. Ormiston JA, Webster MW, Ruygrok PN, Stewart JT, White HD, Scott DS. Stent deformation following simulated side-branch dilatation: a comparison of five stent designs. *Catheter Cardiovasc Interv*. 1999;47:258-64.
14. Hildick-Smith D, Lassen JF, Albiero R, Lefevre T, Darremont O, Pan M, Ferenc M, Stankovic G, Louvard Y; European Bifurcation Club. Consensus from the 5th European Bifurcation Club meeting. *EuroIntervention*. 2010;6:34-8.
15. Lassen JF, Holm NR, Stankovic G, Lefevre T, Chieffo A, Hildick-Smith D, Pan M, Darremont O, Albiero R, Ferenc M, Louvard Y. Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings. *EuroIntervention*. 2014;10:545-60.
16. Ormiston JA, Currie E, Webster MW, Kay P, Ruygrok PN, Stewart JT, Padgett RC, Panther MJ. Drug-eluting stents for coronary bifurcations: insights into the crush technique. *Catheter Cardiovasc Interv*. 2004;63:332-6.
17. Ormiston JA, Webster MW, Webber B, Stewart JT, Ruygrok PN, Hatrick RI. The "crush" technique for coronary bifurcation stenting: insights from micro-computed tomographic imaging of bench deployments. *JACC Cardiovasc Interv*. 2008;1:351-7.
18. Shama SK, Choudhury A, Lee J, Kim MC, Fisher E, Steinheimer AM, Kini AS. Simultaneous kissing stents (SKS) technique for treating bifurcation lesions in medium-to-large size coronary arteries. *Am J Cardiol*. 2004;94:913-7.




Online Figure 1. Absorb scaffold post-dilatation and fracture. A 3.0 mm Absorb scaffold post-dilated with increasing non-compliant balloon diameters and increasing pressure caused straightening and stretching of sinusoidal hoops (A-D). In this individual scaffold strut fracture occurred with a 4.0 mm balloon inflated to 14 atm (E & F).



Online Figure 2. Mini-crush Absorb scaffold deployment. Deployment of the main branch 3.5 mm scaffold (white) has crushed a short length of 3.0 mm side branch scaffold (red) (C,D). Yellow arrows indicate the three layers of crushed strut each 157 μ m thick (A,B). Main branch scaffold post-dilatation with a 3.5 mm NC balloon was followed sequentially by a side branch post-dilatation with a 3.0 mm NC balloon each at 16 atm then kissing post-dilatation (same balloons) at 5 atm. The side branch struts (red) have not been fully cleared from the side branch ostium (D). Broken yellow line: side branch ostium; broken blue line: lumen free of struts.



Online Figure 3. Simultaneous kissing scaffolds (SKS). While the scaffolds can be deployed simultaneously through a large guide, the same result can be achieved by sequential deployment then kissing post-dilatation. The lumens are asymmetrical (A & C). Two layers of struts partition the main branch (B, yellow oval).



Online Figure 4. Environmental scanning electron microscope images of an Absorb scaffold. Damage to the Absorb polymer coating (black arrows) was caused by withdrawal of a 0.014" BALANCE MIDDLEWEIGHT guidewire (Abbott Vascular) trapped between the scaffold and phantom.